Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin hydrochloride capsules, usp are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin hydrochloride capsules, usp are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of colitis, as described in the boxed warning , before selecting clindamycin hydrochloride capsules, usp, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastr

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

clinical solutions wholesale, llc - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin hydrochloride capsules, usp are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin hydrochloride capsules, usp are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of colitis, as described in the boxed warning , before selecting clindamycin hydrochloride capsules, usp, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin hydrochloride capsules are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin hydrochloride capsules are also indicated in the treatment of seri‑ous infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of colitis, as described in the boxed warning , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastroin‑testinal tract); infect

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - clindamycin hydrochloride, quantity: 162.87 mg - capsule, hard - excipient ingredients: maize starch; titanium dioxide; lactose monohydrate; gelatin; iron oxide black; shellac; magnesium stearate; purified talc - clindamycin hydrochloride capsules are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin capsules are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. anaerobes serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and skin structure infections; septicaemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, non-gonococcal tubo-ovarian abscess, pelvic cellulitis and post-surgical vaginal cuff infection. streptococci serious respiratory tract infections; serious skin and skin structure infections, septicaemia. staphylococci serious respiratory tract infections; serious skin and skin structure infections; septicaemia; acute haematogenous osteomyelitis. pneumococci serious respiratory tract infections. adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. indicated surgical procedures should be performed in conjunction with antibiotic therapy. bacteriological studies should be performed to determine the causative organisms and their susceptibility to clindamycin.

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin hydrochloride capsules, usp are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin hydrochloride capsules, usp are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of colitis, as described in the boxed warning , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. streptococci: serious respiratory tract infections; serious skin and soft tissue infections. staphylococci: serious respiratory tract infections; serious skin and soft tissue infections. pneumococci: serious respiratory tract infections. bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. to reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules, usp and other antibacterial drugs, clindamycin hydrochloride capsules, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. clindamycin hydrochloride capsules are contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

preferred pharmaceuticals inc - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin hydrochloride capsules, usp are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin hydrochloride capsules, usp are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of colitis, as described in the boxed warning , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infectio

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

remedyrepack inc. - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin hydrochloride capsules, usp are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin hydrochloride capsules, usp are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of colitis, as described in the boxed warning , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. streptococci: serious respiratory tract infections; serious skin and soft tissue infections. staphylococci: serious respiratory tract infections; serious skin and soft tissue infections. pneumococci: serious respiratory tract infections. bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. to reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules, usp and other antibacterial drugs, clindamycin hydrochloride capsules, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. clindamycin hydrochloride capsules are contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

remedyrepack inc. - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin hydrochloride capsules, usp are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin hydrochloride capsules, usp are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of colitis, as described in the boxed warning , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. streptococci: serious respiratory tract infections; serious skin and soft tissue infections. staphylococci: serious respiratory tract infections; serious skin and soft tissue infections. pneumococci: serious respiratory tract infections. bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. to reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules, usp and other antibacterial drugs, clindamycin hydrochloride capsules, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. clindamycin hydrochloride capsules are contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

cardinal health 107, llc - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin hydrochloride capsules, usp are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin hydrochloride capsules, usp are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of colitis, as described in the boxed warning , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. streptococci: serious respiratory tract infections; serious skin and soft tissue infections. staphylococci: serious respiratory tract infections; serious skin and soft tissue infections. pneumococci: serious respiratory tract infections. bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. to reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules, usp and other antibacterial drugs, clindamycin hydrochloride capsules, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. clindamycin hydrochloride capsules are contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - clindamycin hydrochloride (unii: t20oq1yn1w) (clindamycin - unii:3u02el437c) - clindamycin hydrochloride capsules, usp are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. clindamycin hydrochloride capsules, usp are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of colitis, as described in the boxed warning , before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). anaerobes: serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tra